{
    "hands_on_practices": [
        {
            "introduction": "Effective management of age-related macular degeneration begins with accurate risk stratification, which is vital for patient counseling and determining appropriate follow-up intervals. The Age-Related Eye Disease Study (AREDS) provided a foundational, simplified scoring system based on fundus findings that allows clinicians to estimate the long-term risk of progression to advanced disease. This exercise challenges you to apply this clinical grading system to a patient vignette and translate the resulting score into a quantitative risk using a common epidemiological model based on odds ratios .",
            "id": "4650558",
            "problem": "A patient is seen with age-related macular degeneration (AMD) in both eyes. On dilated fundus examination of each eye, there are large drusen with diameter $\\geq 125 \\ \\mu \\mathrm{m}$ and definite pigmentary abnormalities in the macula. There are no signs of advanced age-related macular degeneration (geographic atrophy involving the foveal center or neovascular AMD) in either eye.\n\nUse the Age-Related Eye Disease Study (AREDS) simplified severity scale, defined as follows: for each eye, assign $1$ point for the presence of large drusen and $1$ point for the presence of definite pigmentary abnormalities; if advanced age-related macular degeneration is present in an eye, that eye contributes $2$ points. The total AREDS simplified score is the sum across both eyes and ranges from $0$ to $4$.\n\nAssume the following risk model for $5$-year progression to advanced age-related macular degeneration: when the total AREDS simplified score is $s=0$, the baseline $5$-year absolute risk is $p_0=0.005$. For each one-point increase in the total score, the $5$-year odds of progression are multiplied by a constant factor $\\theta=4$.\n\nBased on these assumptions and the examination findings, compute the patient’s total AREDS simplified score $s$ and then compute the corresponding absolute $5$-year risk of progression. Round your answer to $4$ significant figures. Express the final risk as a decimal fraction with no percent sign. Provide only the risk value as your final answer.",
            "solution": "The problem is valid as it is scientifically grounded in the principles of clinical ophthalmology and biostatistics, specifically using the well-established Age-Related Eye Disease Study (AREDS) framework. The problem is well-posed, objective, and provides all necessary information to compute a unique solution.\n\nThe solution process consists of two main steps: first, determining the patient's total AREDS simplified score based on the provided clinical findings, and second, using the given risk model to calculate the $5$-year absolute risk of progression to advanced age-related macular degeneration (AMD).\n\n**Step 1: Calculation of the Total AREDS Simplified Score ($s$)**\n\nThe AREDS simplified severity scale is defined by assigning points to each eye based on specific findings. The total score, $s$, is the sum of points from both eyes.\n\nFor the right eye:\n- The presence of large drusen with a diameter $\\geq 125 \\ \\mu \\mathrm{m}$ contributes $1$ point.\n- The presence of definite pigmentary abnormalities contributes $1$ point.\n- The problem explicitly states there are no signs of advanced AMD, so the rule for advanced AMD (which would assign $2$ points) does not apply.\nThe score for the right eye is therefore $1 + 1 = 2$.\n\nFor the left eye:\n- The problem states that the findings are present in \"both eyes\", so the condition of the left eye is identical to the right eye.\n- The presence of large drusen contributes $1$ point.\n- The presence of definite pigmentary abnormalities contributes $1$ point.\n- There are no signs of advanced AMD.\nThe score for the left eye is also $1 + 1 = 2$.\n\nThe total AREDS simplified score, $s$, is the sum of the scores from both eyes:\n$$s = (\\text{score for right eye}) + (\\text{score for left eye}) = 2 + 2 = 4$$\n\n**Step 2: Calculation of the 5-Year Absolute Risk of Progression**\n\nThe problem provides a risk model based on odds. The relationship between probability, $p$, and odds, $O$, is given by:\n$$O = \\frac{p}{1-p} \\quad \\text{and} \\quad p = \\frac{O}{1+O}$$\n\nFirst, we determine the baseline odds of progression, $O_0$, corresponding to a total score of $s=0$. The baseline $5$-year absolute risk is given as $p_0 = 0.005$.\n$$O_0 = \\frac{p_0}{1-p_0} = \\frac{0.005}{1-0.005} = \\frac{0.005}{0.995}$$\n\nThe model states that for each one-point increase in the total score, the $5$-year odds of progression are multiplied by a constant factor $\\theta = 4$. This implies an exponential relationship between the odds and the score:\n$$O_s = O_0 \\cdot \\theta^s$$\nwhere $O_s$ is the odds of progression for a patient with a total score of $s$.\n\nFor this patient, the total score is $s=4$. We can now calculate the corresponding odds of progression, $O_4$:\n$$O_4 = O_0 \\cdot \\theta^4 = \\left( \\frac{0.005}{0.995} \\right) \\cdot 4^4$$\nSince $4^4 = 256$, we have:\n$$O_4 = \\frac{0.005 \\times 256}{0.995} = \\frac{1.28}{0.995}$$\n\nNow, we convert these odds back to a probability (absolute risk), $p_4$:\n$$p_4 = \\frac{O_4}{1+O_4} = \\frac{\\frac{1.28}{0.995}}{1 + \\frac{1.28}{0.995}}$$\nTo simplify this complex fraction, we multiply the numerator and denominator by $0.995$:\n$$p_4 = \\frac{1.28}{0.995 + 1.28} = \\frac{1.28}{2.275}$$\n\nPerforming the final division:\n$$p_4 \\approx 0.56263736...$$\n\nThe problem requires rounding the final answer to $4$ significant figures.\nThe first four significant figures are $5$, $6$, $2$, and $6$. The fifth significant figure is $3$, which is less than $5$, so we round down (i.e., we do not change the fourth digit).\n$$p_4 \\approx 0.5626$$\nThis is the patient's absolute $5$-year risk of progression to advanced AMD.",
            "answer": "$$\n\\boxed{0.5626}\n$$"
        },
        {
            "introduction": "Optical Coherence Tomography (OCT) has revolutionized the diagnosis and management of neovascular AMD, but its power is contingent on accurate image interpretation. Distinguishing true pathology from imaging artifacts is a critical skill, as artifacts can mimic disease, leading to misdiagnosis, or obscure pathology, delaying necessary treatment. This practice will test your understanding of OCT signal generation and processing principles by asking you to differentiate between genuine pathological findings and common artifacts like motion, shadowing, and segmentation errors .",
            "id": "4650507",
            "problem": "A 76-year-old patient with known neovascular age-related macular degeneration (AMD) undergoes Spectral-Domain Optical Coherence Tomography (SD-OCT), a modality based on low-coherence interferometry in which axial reflectivity profiles (A-scans) are sampled at a rate $f_s$ and assembled into cross-sectional images (B-scans). The amplitude of the detected OCT signal from depth $z$ depends on backscattering from refractive index discontinuities and is attenuated by absorption and scattering following exponential decay consistent with the Beer–Lambert law. Patient motion during acquisition can cause spatial sampling inconsistencies between adjacent A-scans, and automated layer segmentation uses intensity gradient-based heuristics to place boundary lines (e.g., for the retinal pigment epithelium and external limiting membrane).\n\nOn the current SD-OCT series, the following image features are described. For each feature, you must decide whether it most consistently represents an OCT artifact rather than true pathology and justify the distinction on the basis of first principles about signal formation, attenuation, sampling, and segmentation. Select all options that correctly identify an artifact and correctly differentiate it from true macular pathology in AMD:\n\nA. Across the B-scan, there are alternating vertical bands of slightly lower and higher intensity, with abrupt lateral discontinuities in vessel shadow alignment when comparing adjacent B-scans; retinal layer contours appear stepwise shifted between neighboring segments without consistent deformation in any one area.\n\nB. A sharply demarcated hyporeflective space beneath the retinal pigment epithelium (RPE) elevates it into a smooth, dome-shaped contour; the internal space has uniform low reflectivity and persists with similar size and shape on repeat scans performed minutes later, with associated shallow subretinal hyperreflective material superiorly.\n\nC. Immediately deep to a focal, intensely hyperreflective intraretinal lesion at the level of the inner nuclear layer, there is a well-delineated column of signal dropout extending toward the choroid, while adjacent regions at the same depth retain normal speckled reflectivity and recognizable choroidal vascular patterns.\n\nD. The automated segmentation overlays show the external limiting membrane (ELM) and ellipsoid zone lines displaced and intermittently diving into the choroid in low-signal regions, whereas inspection of the raw grayscale image shows a single continuous hyperreflective band at the expected photoreceptor level without true duplication; measured central subfield thickness changes by $< 5 \\ \\mu\\mathrm{m}$ after manual correction.\n\nE. Multiple ovoid hyporeflective spaces with thin hyperreflective septations occupy the inner retina and coalesce centrally, with measurable increase in central subfield thickness of $> 100 \\ \\mu\\mathrm{m}$ compared with prior baseline; the spaces are contiguous with the foveal depression and have smooth margins.\n\nF. The entire retina appears duplicated and inverted below a central reference line, with mirror-symmetric features and identical distances from the reference line; when the focus and reference arm are adjusted, the duplication disappears and the true retina occupies the upper half of the frame.\n\nChoose all that apply.",
            "solution": "The problem statement is subjected to validation prior to providing a solution.\n\n**Step 1: Extract Givens**\n- Patient: A $76$-year-old with known neovascular age-related macular degeneration (AMD).\n- Modality: Spectral-Domain Optical Coherence Tomography (SD-OCT).\n- Principle of SD-OCT: Low-coherence interferometry; axial reflectivity profiles (A-scans) sampled at rate $f_s$ are assembled into B-scans.\n- Signal Formation: Signal amplitude depends on backscattering from refractive index discontinuities.\n- Signal Attenuation: Signal is attenuated by absorption and scattering, following exponential decay (Beer–Lambert law).\n- Artifact Source 1 (Motion): Patient motion during acquisition causes spatial sampling inconsistencies between adjacent A-scans.\n- Artifact Source 2 (Segmentation): Automated layer segmentation uses intensity gradient-based heuristics to place boundary lines.\n- Task: For each feature (A-F), determine if it represents an OCT artifact rather than true pathology, justifying the distinction based on the principles of signal formation, attenuation, sampling, and segmentation.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically sound, well-posed, and objective. It accurately describes the fundamental principles of SD-OCT, including interferometry, signal attenuation (Beer-Lambert law), image construction from A-scans, and common sources of artifacts such as patient motion and automated segmentation errors. The descriptions of potential image findings are clinically realistic and allow for a rigorous differential between true pathology common in AMD and imaging artifacts. The problem is self-contained and presents no contradictions or ambiguities.\n\n**Verdict:** The problem is valid.\n\n**Solution Derivation and Option Analysis**\n\nThe task is to identify which of the described OCT findings are artifacts, based on the principles of OCT signal acquisition, processing, and display. Each option will be evaluated against these principles.\n\n**A. Across the B-scan, there are alternating vertical bands of slightly lower and higher intensity, with abrupt lateral discontinuities in vessel shadow alignment when comparing adjacent B-scans; retinal layer contours appear stepwise shifted between neighboring segments without consistent deformation in any one area.**\nThis description details a classic **motion artifact**. A B-scan is constructed by acquiring a series of A-scans sequentially in a line. The principle being violated here is **consistent spatial sampling**. If the patient moves (e.g., a small, quick eye movement or saccade) during the scan acquisition, adjacent A-scans or blocks of A-scans will sample different physical locations on the retina than intended. When these misaligned scans are \"stitched\" together to form the B-scan, it results in abrupt vertical breaks, stepwise shifts in retinal layers, and misalignment of continuous structures like vessel shadows. True pathology, such as retinal edema or detachment, would cause smooth deformation of retinal layers, not sharp, geographically inconsistent vertical shifts across the entire image. The described features are a direct consequence of inconsistent sampling due to motion.\n\nVerdict: **Correct**. This option accurately describes a motion artifact and correctly differentiates it from the typical appearance of macular pathology.\n\n**B. A sharply demarcated hyporeflective space beneath the retinal pigment epithelium (RPE) elevates it into a smooth, dome-shaped contour; the internal space has uniform low reflectivity and persists with similar size and shape on repeat scans performed minutes later, with associated shallow subretinal hyperreflective material superiorly.**\nThis describes **true pathology**, specifically a pigment epithelial detachment (PED), which is common in neovascular AMD. The hyporeflective space corresponds to serous or serosanguinous fluid, which has a low backscattering coefficient, appearing dark on the OCT. The dome-shaped elevation of the RPE is the characteristic morphological presentation of a PED. The persistence of the feature on repeat scans confirms it is a stable anatomical structure, not a transient artifact. The associated hyperreflective material is likely fibrin or another component of the choroidal neovascular membrane complex. This finding is not an artifact of signal formation, attenuation, or processing.\n\nVerdict: **Incorrect**. This option describes a classic sign of active neovascular AMD, which is true pathology.\n\n**C. Immediately deep to a focal, intensely hyperreflective intraretinal lesion at the level of the inner nuclear layer, there is a well-delineated column of signal dropout extending toward the choroid, while adjacent regions at the same depth retain normal speckled reflectivity and recognizable choroidal vascular patterns.**\nThis describes a **shadowing artifact**. The governing principle is **signal attenuation**, consistent with the Beer–Lambert law. The intensely hyperreflective lesion (which is itself pathology, such as a hemorrhage or hard exudate) strongly scatters or absorbs the incident OCT light beam. Consequently, insufficient light penetrates to the layers deep to this lesion (the outer retina and choroid). The OCT system detects little to no backscattered signal from this region, creating a \"shadow\" or a column of signal dropout. The proof that this is an artifact is that adjacent areas at the same depth, where the overlying retina is less attenuating, show normal signal. The signal dropout does not represent a true absence of tissue (e.g., atrophy) in the choroid but rather a lack of signal due to obstruction.\n\nVerdict: **Correct**. This option accurately describes a shadowing artifact resulting from signal attenuation by an overlying pathological lesion.\n\n**D. The automated segmentation overlays show the external limiting membrane (ELM) and ellipsoid zone lines displaced and intermittently diving into the choroid in low-signal regions, whereas inspection of the raw grayscale image shows a single continuous hyperreflective band at the expected photoreceptor level without true duplication; measured central subfield thickness changes by $< 5 \\ \\mu\\mathrm{m}$ after manual correction.**\nThis is a textbook example of a **segmentation artifact**. The problem statement specifies that segmentation algorithms use \"intensity gradient-based heuristics.\" In regions of low signal-to-noise ratio or where pathology alters the expected layer reflectivity, these algorithms can fail. They may incorrectly identify the boundaries of retinal layers. The description explicitly states that the raw image shows a continuous band, proving the underlying anatomy is intact. The automated overlay is therefore erroneous. The final confirmation is that manual correction of the segmentation lines leads to a negligible change in measured thickness ($< 5 \\ \\mu\\mathrm{m}$), indicating the initial, algorithm-driven measurement was flawed due to the misplacement of the boundary lines. This is a post-processing error, not a true anatomical disruption.\n\nVerdict: **Correct**. This option accurately describes a segmentation algorithm failure and correctly uses the raw image data and post-correction metrics to confirm it as an artifact.\n\n**E. Multiple ovoid hyporeflective spaces with thin hyperreflective septations occupy the inner retina and coalesce centrally, with measurable increase in central subfield thickness of $> 100 \\ \\mu\\mathrm{m}$ compared with prior baseline; the spaces are contiguous with the foveal depression and have smooth margins.**\nThis describes **true pathology**, specifically cystoid macular edema (CME). The ovoid hyporeflective spaces are fluid-filled cysts within the retinal layers. The septations are stretched retinal tissue, primarily Müller cells. A thickness increase of $> 100 \\ \\mu\\mathrm{m}$ is a significant, quantitative measure of pathological fluid accumulation. This morphology and the associated thickening are hallmarks of edema and are not explainable by any known OCT artifact. This is a direct visualization of pathological anatomical change.\n\nVerdict: **Incorrect**. This option describes cystoid macular edema, which is a form of true pathology.\n\n**F. The entire retina appears duplicated and inverted below a central reference line, with mirror-symmetric features and identical distances from the reference line; when the focus and reference arm are adjusted, the duplication disappears and the true retina occupies the upper half of the frame.**\nThis describes a **mirror artifact**. The principle of **signal formation** in Fourier-Domain OCT (which includes SD-OCT) is key. The Fourier transform of the real-valued spectral interferogram is conjugate-symmetric. This means the system cannot distinguish signal arriving from a distance $+\\Delta z$ from the zero-delay plane from a signal arriving from $-\\Delta z$. To avoid this ambiguity, the zero-delay plane (the point of zero path-length difference between reference and sample arms) is normally set anterior to the tissue of interest. If it is incorrectly placed within the retina, the part of the retina located \"behind\" this plane is \"folded over\" and displayed as an inverted mirror image. The facts that the image is perfectly symmetric and that the artifact is resolved by adjusting the instrument's reference arm prove it is a setup-dependent artifact, not a biological structure.\n\nVerdict: **Correct**. This option accurately describes a mirror artifact based on the fundamental principles of Fourier-Domain OCT signal processing.\n\nThe options that correctly identify an artifact and differentiate it from true pathology are A, C, D, and F.",
            "answer": "$$\\boxed{ACDF}$$"
        },
        {
            "introduction": "The treatments we prescribe for AMD are validated by large-scale, randomized clinical trials, which form the bedrock of evidence-based ophthalmology. To critically appraise the medical literature and understand the strength of the evidence supporting a given therapy, it is essential to grasp the fundamentals of clinical trial design. This problem provides a hands-on opportunity to perform a crucial step in designing a clinical trial: calculating the required sample size to ensure a study has adequate statistical power to detect a clinically meaningful treatment effect .",
            "id": "4650581",
            "problem": "A randomized, double-masked, parallel-group clinical trial is planned to compare two intravitreal treatment regimens for neovascular age-related macular degeneration (AMD). The primary endpoint is the mean change from baseline in best-corrected visual acuity (BCVA) measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters at $12$ months. Investigators regard a true between-group mean difference of $\\delta = 5$ ETDRS letters as clinically meaningful. Prior data suggest that the change scores in each arm are approximately Gaussian with a common standard deviation $\\sigma = 10$ ETDRS letters. Allocation will be $1{:}1$. A two-sided hypothesis test of $H_{0}: \\mu_{1} - \\mu_{2} = 0$ will be used with Type I error rate $\\alpha = 0.05$, and the desired power is $1 - \\beta = 0.8$. Assume independence between arms, normality of the mean change, known and equal variance across arms, and use the large-sample Wald $Z$-test for the difference in means.\n\nStarting from the sampling distribution of the difference in independent Gaussian means and the definitions of Type I and Type II errors for a two-sided test, derive the minimal equal per-arm sample size required to achieve the specified power to detect the targeted mean difference. Express the final per-arm sample size as the smallest integer $n$ that satisfies the power criterion (i.e., apply the ceiling function to the computed real-valued solution). Do not inflate for attrition. Provide the final per-arm sample size as a single number without units.",
            "solution": "Under the model assumptions, let $X_{1,1}, \\dots, X_{1,n}$ be the change scores in arm $1$ and $X_{2,1}, \\dots, X_{2,n}$ in arm $2$, with $X_{1,i} \\stackrel{\\text{iid}}{\\sim} \\mathcal{N}(\\mu_{1}, \\sigma^{2})$ and $X_{2,j} \\stackrel{\\text{iid}}{\\sim} \\mathcal{N}(\\mu_{2}, \\sigma^{2})$, independent across arms. The sample means satisfy $\\bar{X}_{1} \\sim \\mathcal{N}(\\mu_{1}, \\sigma^{2}/n)$ and $\\bar{X}_{2} \\sim \\mathcal{N}(\\mu_{2}, \\sigma^{2}/n)$, independent. Therefore, the difference $D = \\bar{X}_{1} - \\bar{X}_{2}$ has distribution\n$$\nD \\sim \\mathcal{N}\\!\\left(\\mu_{1} - \\mu_{2}, \\frac{\\sigma^{2}}{n} + \\frac{\\sigma^{2}}{n}\\right) = \\mathcal{N}\\!\\left(\\mu_{1} - \\mu_{2}, \\frac{2\\sigma^{2}}{n}\\right).\n$$\nDefine the standard error $SE = \\sqrt{2\\sigma^{2}/n} = \\sigma \\sqrt{2/n}$. The two-sided Wald $Z$-test rejects $H_{0}: \\mu_{1} - \\mu_{2} = 0$ when $|D| \\ge z_{1-\\alpha/2} \\, SE$, where $z_{q}$ denotes the $q$-quantile of the standard normal distribution.\n\nPower is $1 - \\beta = \\mathbb{P}(\\text{reject } H_{0} \\mid \\mu_{1} - \\mu_{2} = \\delta)$ for the targeted true effect $\\delta = 5$. With $\\delta > 0$, a sufficient (conservative for two-sided testing) condition for achieving the desired power is to require\n$$\n\\mathbb{P}\\!\\left(D \\ge z_{1-\\alpha/2} \\, SE \\,\\middle|\\, \\mu_{1} - \\mu_{2} = \\delta \\right) \\;=\\; 1 - \\beta.\n$$\nStandardizing using $Z = (D - \\delta)/SE \\sim \\mathcal{N}(0,1)$ under the alternative yields\n$$\n\\mathbb{P}\\!\\left(Z \\ge \\frac{z_{1-\\alpha/2} \\, SE - \\delta}{SE} \\right) = 1 - \\beta\n\\;\\;\\Longleftrightarrow\\;\\;\n\\frac{z_{1-\\alpha/2} \\, SE - \\delta}{SE} = z_{1-\\beta}.\n$$\nSolving for $n$ gives\n$$\n\\frac{\\delta}{SE} = z_{1-\\alpha/2} + z_{1-\\beta}\n\\;\\;\\Longleftrightarrow\\;\\;\n\\frac{\\delta}{\\sigma \\sqrt{2/n}} = z_{1-\\alpha/2} + z_{1-\\beta}\n\\;\\;\\Longleftrightarrow\\;\\;\nn = \\frac{2\\sigma^{2}\\,\\big(z_{1-\\alpha/2} + z_{1-\\beta}\\big)^{2}}{\\delta^{2}}.\n$$\n\nNow substitute the design parameters $\\alpha = 0.05$, $1 - \\beta = 0.8$ (so $\\beta = 0.2$), $\\sigma = 10$, and $\\delta = 5$. The relevant normal quantiles are $z_{1-\\alpha/2} = z_{0.975} \\approx 1.959963984$ and $z_{1-\\beta} = z_{0.8} \\approx 0.841621234$.\nCompute\n$$\nz_{1-\\alpha/2} + z_{1-\\beta} \\approx 1.959963984 + 0.841621234 \\approx 2.801585218,\n$$\n$$\n\\big(z_{1-\\alpha/2} + z_{1-\\beta}\\big)^{2} \\approx (2.801585218)^{2} \\approx 7.848877.\n$$\nTherefore,\n$$\nn \\approx \\frac{2 \\times (10)^{2} \\times 7.848877}{(5)^{2}} \\;=\\; \\frac{200 \\times 7.848877}{25} \\;=\\; 8 \\times 7.848877 \\;\\approx\\; 62.790996.\n$$\nThe minimal equal per-arm sample size is obtained by applying the ceiling function to ensure the power criterion is met:\n$$\nn_{\\text{per arm}} = \\lceil 62.790996 \\rceil = 63.\n$$\nThus, the required per-arm sample size is $63$ participants.",
            "answer": "$$\\boxed{63}$$"
        }
    ]
}